Seven Factors that Increase Mortality Risk in COVID-19 Patients?

Seven factors that increase mortality risk in Covid-19 patients are ECOG-PS, neutrophil count, serum procalcitonin, tumor stage at COVID-19 diagnosis, development of pneumonia, c-reactive protein (CRP) and age.

COVID-19 patients are at increased risk of death and thoracic cancer due to seven major determinants, reveals a new study.

The research was published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

Risk Factors for Long-haul COVID-19 in People With Rheumatic Diseases Identified
Over 50% of rheumatic patients who have contracted COVID during the pandemic had experienced so-called “long-haul” COVID, or prolonged symptoms of the infection, including loss of taste or smell, muscle aches and difficulty concentrating, for one month or longer.

‘The seven factors that increase mortality risk in COVID-19 patients are ECOG-PS, neutrophil count, serum procalcitonin, tumor stage at COVID-19 diagnosis, development of pneumonia, c-reactive protein (CRP), and age.’

The researchers analyzed data from The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT), which is an active global registry that was established in March 2020 to understand the impact of COVID-19 infection on patients with thoracic malignancies in academic and community practices globally.

In total, 114 centers across 19 countries have activated the study, and 92 have contributed data.

Eligibility criteria were patients with thoracic cancer (non-small cell lung cancer [NSCLC], small cell lung cancer, mesothelioma, thymic epithelial tumors, and other neuroendocrine tumors with pulmonary origin) with a COVID-19 diagnosis defined as any of the following: laboratory confirmed (using RT12 PCR/serology) infection; or suspected SARS-CoV-2 infection based on radiological findings consistent with COVID-19 pneumonia and clinical symptoms (i.e., fever >37.5°C, cough, decrease of oxygen saturation of at least 5%, cough, diarrhea, otitis, dysgeusia, myalgia, arthralgia, conjunctivitis, and rhinorrhea).

COVID-19 : How the Risk Factors Contribute to Treatment Options
COVID-19 has greater potency to affect hospitalized patients who are obese, have complications from diabetes or hypertension, especially in men.

In addition to reporting on outcomes associated with morbidity and mortality, TERAVOLT aims to determine the risk factors associated with poor outcomes, as well as provide practitioners with real-time data on therapies that may impact survival to COVID-19 and evaluate long-term impacts on care and the delay in care to patients with both curable and incurable thoracic malignancies.

As of April 15, 2021, the researchers had evaluated 1491 patients from 18 countries. With a mean observation period of 42 days, Cortellini and co-researchers reported 361 events with an all-cause case fatality rate of 24.2%.

Dining Out Increases COVID-19 Risk
Close contact and dining in pubs, restaurants and coffee shops increases the risk of contracting COVID-19. Positive adults were twice as likely to have dined 14 days before the infection.

The fast-backward step-down selection then identified seven major determinants of death from more than 70 variables analyzed:

ECOG-PS (OR 2.47, 1.87–3.26)
Neutrophil count (OR 2.46, 1.76–3.44)
Serum procalcitonin (OR 2.37, 1.64–3.43)
Tumor stage at COVID-19 diagnosis (OR 1.97, 1.46–2.66)
Development of pneumonia (OR 1.95, 1.48–2.58)
C-reactive protein (CRP) (OR 1.90, 1.43–2.51) and
Age (OR 1.71, 1.29–2.26).

Given the disease characteristics and the common target organ, patients with thoracic malignancies have been shown to experience higher morbidity and mortality from SARS-CoV-2 infection, with case fatality rates ranging from 22% to 41% according to literature.

Poor ECOG-PS demonstrated the strongest association with poor outcome from COVID-19.

COVID-19 Disrupts Families: Know More
Family therapy and individual psychotherapy for both parents and kids can be helpful for households struggling with adjustments in response to the Covid-19 pandemic.

“Despite the ongoing efforts including immunization campaigns and increased capacity, SARS-CoV-2 will still impact the continuity of care of patients with cancer, at least to a certain extent. Against the evolving scenario, we provided a comprehensive and powered prognostication system that can be a useful tool for clinicians.” said Alessio Cortellini, MD, from the Imperial College London, London, United Kingdom.

“Currently, this analysis did not look at the impact of COVD-19 vaccination. The TERAVOLT database was recently updated to capture information about vaccination status, as well as information about the specific variants. A separate analysis will be performed with the new data.” said Jennifer G Whisenant, PhD, from the Vanderbilt University, Nashville, Tenn.

This TERAVOLT study was awarded a grant from the Lung Ambition that supported database development and maintenance and acknowledges support from the International Association for the Study of Lung Cancer (IASLC).

Source-Eurekalert